Pilot Investigation of Stem Cells in Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

11 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2022-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study is designed to test the safety of a manufactured neural stem cell line (CTX cells) delivered by injection into the damaged brains of male patients 60 years of age or over who remain moderately to severely disabled 6 months to 5 years following an ischemic stroke. In addition the trial will evaluate a range of potential efficacy measures for future trials. Treatment will involve a single injection of one of four doses of CTX cells into the patient's brain in a carefully controlled neurosurgical operation performed under general anesthetic. The trial is designed to treat 12 patients and measure outcomes over 24 months. Patients will be invited to participate in a long-term follow-up trial for a further 8 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Trial Study About Human Adipose-Derived Stem Cells in the Stroke

NCT02813512

Stroke

COMPLETED PHASE1

Intraarterial Stem Cells in Subacute Ischemic Stroke

NCT03080571

Ischemic Stroke MCA Infarction

COMPLETED PHASE1

A Study of Modified Stem Cells in Stable Ischemic Stroke

NCT01287936

Chronic Ischemic Stroke

COMPLETED PHASE1/PHASE2

BXOS110 Injection in the Treatment of Acute Ischaemic Stroke

NCT06322394

Acute Ischemic Stroke

RECRUITING PHASE2

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke

NCT01310114

Stroke, Acute Middle Cerebral Artery Stroke Posterior Cerebral Artery Stroke

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Design: The trial is an open label, single administration, ascending dose, single site trial using CTX neural stem cells with 24-month patient monitoring following treatment.

Pre-treatment selection of patients : Males aged ≥60 years with unilateral ischaemic stroke affecting sub-cortical white matter and/or basal ganglia 6 months to 5 years prior to entry into the study, with persistent unilateral hemiparesis, a minimum infarct diameter of 1 cm and stable neurological functional deficit as determined by the NIH Stroke Scale, (measured twice at least 1 month apart), will be eligible for treatment.

Treatment: The CTX cells will be injected by stereotaxic procedures into the putamen region of the brain of the patient under general anesthesia with imaging guidance to locate injection site. Four ascending doses of CTX cells will be tested in 12 patients (4 dosage groups of three patients at each dose level receiving 2 million, 5 million, 10 million or 20 million cells). Patients will be admitted to hospital the day before surgery and prepared for CTX cell implantation to take place. Patients will be discharged two days after surgery.

One patient will be treated at a time. An independent Data Safety Monitoring Board (DSMB) will make the decision to continue dosing at each dose level following satisfactory review of the 28 day safety data for the first patient at that dose level; and to increase the dose to the next level following satisfactory review of the 3 month safety data for all three patients in the previous dose group.

Post treatment follow-up of patients: There will be 6 scheduled visits to clinic for monitoring and neurofunctional testing and 5 scheduled telephone contacts to monitor adverse events (AEs) and concomitant medications over the 2 year follow-up period.

End-points: The primary end-point of the trial is safety, measured by numbers of relevant Serious Adverse Events, health screening, neurological assessment and scanning abnormalities. The secondary aim is to evaluate various MRI and other test measures for their potential as efficacy markers for subsequent trials.

Post trial follow up: All trial patients will be flagged by the National Health Service Central Register (NHSCR) Scotland for life-long follow-up. In addition, all patients will be invited to take part in an 8-year follow up trial requiring an annual review by a suitable physician.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CTX0E03 DP

human neural stem cell product, once only injection, increasing doses

Group Type EXPERIMENTAL

CTX0E03 neural stem cells

Intervention Type BIOLOGICAL

Single administration by surgical delivery to the damaged area of the brain

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CTX0E03 neural stem cells

Single administration by surgical delivery to the damaged area of the brain

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males
* 60 years or over
* Unilateral ischemic stroke involving subcortical white matter or Basal Ganglia 6 months to 5 years before entry
* NIHSS score minimum 6 with hemiparesis (2 or more for motor arm and leg)
* Neurologically stable for 2 m
* modified Rankin score of 2-4
* Fit for general anesthesia, neurosurgery
* Capacity to consent
* Infarct at least 1cm diameter

Exclusion Criteria

* Structural brain vascular lesions requiring surgery or increasing the risk of stereotaxic implantation
* Unstable medical conditions with expected survival \<12 months
* Any medical condition that would impair participation (eg progressive neurological disorders, mental illness)
* Major surgery within 30 days
* Previous allogeneic tissue transplant
* MMSE \< 24
* Epilepsy
* Coagulation disorders or anticoagulant treatment that cannot be interrupted
* Stimulants, botox, tamoxifen
* Contraindications to MRI

Minimum Eligible Age

60 Years

Maximum Eligible Age

85 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No